The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses
Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report,...
Saved in:
| Published in | Journal of Virology Vol. 90; no. 6; pp. 3086 - 3092 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
15.03.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits
in vitro
hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses
in vitro
infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.
IMPORTANCE
There are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses. |
|---|---|
| AbstractList | Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits
in vitro
hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses
in vitro
infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.
IMPORTANCE
There are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses. Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality. There are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses. Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.UNLABELLEDArbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality.There are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses.IMPORTANCEThere are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses. Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North America. We have previously shown that ARB inhibits in vitro hepatitis C virus (HCV) by blocking HCV entry and replication. In this report, we expand the list of viruses that are inhibited by ARB and demonstrate that ARB suppresses in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpesvirus 8 (HHV-8). We also confirm suppression of hepatitis B virus and poliovirus by ARB. ARB inhibited EBOV Zaire Kikwit infection when added before or at the same time as virus infection and was less effective when added 24 h after EBOV infection. Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycoprotein showed that infection was inhibited by ARB at early stages, most likely at the level of viral entry into host cells. ARB inhibited HHV-8 replication to a similar degree as cidofovir. Our data broaden the spectrum of antiviral efficacy of ARB to include globally prevalent viruses that cause significant morbidity and mortality. IMPORTANCE: There are many globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Some of these viruses, such as Ebola virus or members of the arenavirus family, rapidly cause severe hemorrhagic diseases that can be fatal. Other viruses, such as hepatitis B virus or human herpesvirus 8 (HHV-8), establish persistent infections that cause chronic illnesses, including cancer. Thus, finding an affordable, effective, and safe drug that blocks many viruses remains an unmet medical need. The antiviral drug arbidol (ARB), already in clinical use in several countries as an anti-influenza treatment, has been previously shown to suppress the growth of many viruses. In this report, we expand the list of viruses that are blocked by ARB in a laboratory setting to include Ebola virus, Tacaribe arenavirus, and HHV-8, and we propose ARB as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses |
| Author | Peter Halfmann Eve Isabelle Pécheur Mark N. Prichard Stephen J. Polyak Donald F. Smee Viktoriya Borisevich Yoshihiro Kawaoka John D. Morrey Thomas W. Geisbert Chad E. Mire |
| Author_xml | – sequence: 1 givenname: Eve-Isabelle surname: Pécheur fullname: Pécheur, Eve-Isabelle organization: CRCL, Inserm U1052, CNRS 5286, University of Lyon, Lyon, France – sequence: 2 givenname: Viktoriya surname: Borisevich fullname: Borisevich, Viktoriya organization: Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA – sequence: 3 givenname: Peter surname: Halfmann fullname: Halfmann, Peter organization: Department of Pathobiological Sciences, University of Wisconsin, Madison, Wisconsin, USA – sequence: 4 givenname: John D. surname: Morrey fullname: Morrey, John D. organization: Institute for Antiviral Research, Utah State University, Logan, Utah, USA – sequence: 5 givenname: Donald F. surname: Smee fullname: Smee, Donald F. organization: Institute for Antiviral Research, Utah State University, Logan, Utah, USA – sequence: 6 givenname: Mark surname: Prichard fullname: Prichard, Mark organization: Department of Pediatrics, University of Alabama School of Medicine, Birmingham, Alabama, USA – sequence: 7 givenname: Chad E. surname: Mire fullname: Mire, Chad E. organization: Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA – sequence: 8 givenname: Yoshihiro surname: Kawaoka fullname: Kawaoka, Yoshihiro organization: Department of Pathobiological Sciences, University of Wisconsin, Madison, Wisconsin, USA, International Research Center for Infectious Diseases and Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 9 givenname: Thomas W. surname: Geisbert fullname: Geisbert, Thomas W. organization: Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA – sequence: 10 givenname: Stephen J. surname: Polyak fullname: Polyak, Stephen J. organization: Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA, Department of Global Health, University of Washington, Seattle, Washington, USA |
| BackLink | https://cir.nii.ac.jp/crid/1873961342658423936$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/26739045$$D View this record in MEDLINE/PubMed https://hal.science/hal-01812681$$DView record in HAL |
| BookMark | eNp1kcFvFCEUxompsWvtzbOZgwdNnMqDgWEuJpuq7ZpNbNLaeCMww-xgZqECO8n-9zJubbSJFyDw-773Pd5zdOS8Mwi9BHwGQMT7H5M9wwTXdQnsCVoAbkTJGFRHaIExISWj4vsxOo3Ragw1q5sGV8_QMeE1zSe2QNc3gymu9y4NJtm2WLpkJxvUWHwMu02xDNp2fixWbrDaplhcjF6rcdwXV8FMajQuFVcqDX5jXFbf2rCLJr5AT3s1RnN6v5-gb58_3ZxfluuvF6vz5bpsGdBUdp3ueA9cK9aC6CtFlOj7jjXU4L5huiOCYQ09FrSnuqO5YVJRblpaE1IDpifow8H3bqe3pmtzmpxc3gW7VWEvvbLy3xdnB7nxk6wEYE54Nnh7MBgeyS6XaznfYRBAuIAJMvvmvljwP3cmJrm1sTXjqJzxuyih5oIxQRnL6Ku_cz04__n1DLw7AG3wMQbTPyCA5TxX-eV2JX_PVcKMk0d4a5NK1s9d2fF_otcHkbM28_MKItfnQCvCmagIbSinvwB6f6_h |
| CitedBy_id | crossref_primary_10_1128_AAC_01146_20 crossref_primary_10_17116_terarkh201789162_71 crossref_primary_10_3390_pr11030922 crossref_primary_10_3390_molecules27092723 crossref_primary_10_21518_2079_701X_2019_2_183_187 crossref_primary_10_3389_fphar_2020_560209 crossref_primary_10_1186_s12879_023_08570_9 crossref_primary_10_2174_1381612827666210701150315 crossref_primary_10_3390_life10080146 crossref_primary_10_3390_ph14060520 crossref_primary_10_4110_in_2021_21_e7 crossref_primary_10_3390_v10050235 crossref_primary_10_1016_j_antiviral_2016_09_001 crossref_primary_10_31857_S0044450223090153 crossref_primary_10_1134_S1061934823090150 crossref_primary_10_2217_fvl_2016_0113 crossref_primary_10_1016_j_bmcl_2017_06_074 crossref_primary_10_1080_17460441_2020_1714586 crossref_primary_10_3389_fphar_2020_607075 crossref_primary_10_3390_jcm9072030 crossref_primary_10_3390_v13071187 crossref_primary_10_1007_s11095_020_02799_8 crossref_primary_10_3389_fimmu_2020_01841 crossref_primary_10_1128_JVI_00941_17 crossref_primary_10_3390_v13081665 crossref_primary_10_1111_zph_12469 crossref_primary_10_57056_ajb_v3i2_65 crossref_primary_10_1016_j_antiviral_2021_105016 crossref_primary_10_1128_aac_01015_23 crossref_primary_10_1016_j_biopha_2021_111966 crossref_primary_10_37489_2588_0519_2020_S4_75_80 crossref_primary_10_2147_JEP_S255209 crossref_primary_10_1007_s11596_020_2203_3 crossref_primary_10_1016_j_imbio_2020_152008 crossref_primary_10_3390_ijms21155224 crossref_primary_10_1099_jgv_0_001283 crossref_primary_10_1007_s42485_021_00074_x crossref_primary_10_1016_j_molliq_2024_124074 crossref_primary_10_3390_ph13080188 crossref_primary_10_3390_ph14060503 crossref_primary_10_3390_ph14060587 crossref_primary_10_3390_ph15030301 crossref_primary_10_1128_JVI_02185_18 crossref_primary_10_2147_RMHP_S265030 crossref_primary_10_1080_14787210_2021_1864327 crossref_primary_10_1080_14787210_2020_1782742 crossref_primary_10_1007_s00705_021_05230_8 crossref_primary_10_1073_pnas_1617020114 crossref_primary_10_1016_j_ejmech_2020_112687 crossref_primary_10_3389_fmicb_2024_1382953 crossref_primary_10_1002_jmv_25707 crossref_primary_10_1128_AAC_01302_18 crossref_primary_10_1039_D3MD00677H crossref_primary_10_1016_j_scitotenv_2021_150380 crossref_primary_10_1002_ddr_21720 crossref_primary_10_3390_org4020012 crossref_primary_10_1016_j_lfs_2020_117883 crossref_primary_10_1016_j_phrs_2020_104859 crossref_primary_10_1016_j_biopha_2017_04_091 crossref_primary_10_1186_s12879_020_05698_w crossref_primary_10_1007_s11010_020_03981_7 crossref_primary_10_1002_med_21763 crossref_primary_10_15789_2220_7619_2018_2_195_200 crossref_primary_10_1016_j_virusres_2020_198262 crossref_primary_10_1016_j_bcp_2020_114169 crossref_primary_10_3390_v10040184 crossref_primary_10_1002_jhet_4778 crossref_primary_10_1002_jmv_26129 crossref_primary_10_1016_j_tim_2020_10_011 crossref_primary_10_1080_13543784_2021_1881061 crossref_primary_10_1002_ardp_201800225 crossref_primary_10_1002_iid3_984 crossref_primary_10_1007_s00705_022_05368_z crossref_primary_10_26442_00403660_2019_03_000127 crossref_primary_10_1002_iid3_502 crossref_primary_10_1016_j_ejps_2020_105522 crossref_primary_10_1038_s41598_018_27224_4 crossref_primary_10_2147_IJN_S315705 crossref_primary_10_3390_molecules27227940 crossref_primary_10_1016_j_ejphar_2020_173836 crossref_primary_10_1007_s00232_016_9876_3 crossref_primary_10_36502_2020_hcr_6179 crossref_primary_10_1016_j_snb_2024_136519 crossref_primary_10_1016_j_coviro_2019_03_001 crossref_primary_10_3390_separations10070379 crossref_primary_10_1016_j_virol_2018_08_011 crossref_primary_10_1051_medsci_20163212004 crossref_primary_10_1016_j_biopha_2021_111642 crossref_primary_10_1002_jmv_26142 crossref_primary_10_1007_s11356_021_16809_8 crossref_primary_10_3390_molecules28217427 crossref_primary_10_1177_17534666231183811 crossref_primary_10_1007_s40495_020_00216_7 crossref_primary_10_2139_ssrn_3919585 crossref_primary_10_1007_s00044_020_02625_1 crossref_primary_10_1016_j_scitotenv_2024_177175 crossref_primary_10_1016_j_antiviral_2018_09_016 crossref_primary_10_1016_j_bioorg_2021_105016 crossref_primary_10_1073_pnas_2006893117 crossref_primary_10_1038_s41401_020_0438_y crossref_primary_10_3389_fphar_2020_01196 crossref_primary_10_1016_j_micinf_2020_05_012 crossref_primary_10_1111_febs_16662 crossref_primary_10_1016_j_bsheal_2021_01_001 |
| Cites_doi | 10.1056/NEJMc1401726 10.1371/journal.pone.0015874 10.1128/jvi.69.10.6158-6169.1995 10.1038/nm.2581 10.1126/scitranslmed.aaa5597 10.1097/00063198-200405000-00009 10.1371/journal.ppat.1001110 10.1074/jbc.M601418200 10.1016/j.tim.2015.04.006 10.1038/nm.2341 10.1128/JVI.02498-08 10.1128/JVI.00253-07 10.1016/j.virol.2007.07.014 10.1371/journal.ppat.1000512 10.1128/AAC.48.5.1766-1772.2004 10.1016/j.bmc.2005.08.041 10.1073/pnas.84.4.1005 10.1128/AAC.48.6.2199-2205.2004 10.1016/j.antiviral.2011.03.182 10.1128/AAC.00356-07 10.1371/journal.ppat.1001121 10.1093/infdis/jiu222 10.2174/092986708784049658 10.1128/JVI.77.14.7978-7990.2003 10.1128/AAC.00429-13 10.1016/j.bmc.2005.11.033 10.1002/jmv.22234 10.1016/j.antiviral.2014.04.006 10.1016/0042-6822(89)90286-9 10.1371/journal.ppat.1002905 10.1016/j.antiviral.2013.08.008 10.1186/1743-422X-3-56 10.1056/NEJM199505043321801 10.3390/molecules16010221 10.1038/nrmicro1645 10.1093/infdis/jir326 10.1074/jbc.M109.014647 10.1371/journal.pone.0115769 10.1111/j.1742-4658.2009.07402.x 10.1007/s00018-007-7291-8 10.1016/j.cell.2005.12.038 10.1016/0042-6822(84)90102-8 10.1371/journal.pntd.0002748 10.1016/S0140-6736(12)61728-0 10.1038/nm0396-342 10.1021/bi700181j 10.1016/j.antiviral.2013.08.021 10.1099/jmm.0.076612-0 |
| ContentType | Journal Article |
| Contributor | Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Contributor_xml | – sequence: 1 fullname: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) – sequence: 2 fullname: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL) ; Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Copyright | Copyright © 2016, American Society for Microbiology. All Rights Reserved. Distributed under a Creative Commons Attribution 4.0 International License Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
| Copyright_xml | – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC 5PM |
| DOI | 10.1128/jvi.02077-15 |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| DocumentTitleAlternate | Broad-Spectrum Antiviral Activity of Arbidol |
| EISSN | 1098-5514 |
| EndPage | 3092 |
| ExternalDocumentID | PMC4810626 oai_HAL_hal_01812681v1 26739045 10_1128_JVI_02077_15 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272201100016C – fundername: NIAID NIH HHS grantid: HHSN272201000039C – fundername: NIAID NIH HHS grantid: HHSN272201100019C – fundername: NIAID NIH HHS grantid: HHSN272201100019I – fundername: NIAID NIH HHS grantid: HHSN272201000039I |
| GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S AAFWJ AAGFI ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A O9- OK1 P2P RHI RNS RPM RSF RYH TR2 UPT W2D W8F WH7 WOQ YQT ~02 ~KM AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 .55 .GJ 1XC 3O- 41~ 6TJ AAYJJ AFFNX AI. C1A D0S MVM OHT UMC VH1 X7M Y6R ZGI ZXP 5PM |
| ID | FETCH-LOGICAL-c513t-ddbd6f16ba5c18f4a2a8ffd593e0f95bd2850b1f083f3bd31122436ec37227103 |
| ISSN | 0022-538X 1098-5514 |
| IngestDate | Thu Aug 21 13:53:20 EDT 2025 Fri May 09 12:07:25 EDT 2025 Fri Jul 11 06:59:19 EDT 2025 Thu Apr 03 07:04:28 EDT 2025 Thu Apr 24 23:01:28 EDT 2025 Tue Jul 01 01:02:43 EDT 2025 Fri Jun 27 00:42:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Pediatrics Laboratories Growth Humans Viruses Time Molecular Virus Internalization Microbial Sensitivity Tests Hepatitis pharmacology Molecular Structure Hepatitis B virus Indoles France immunology Cell Line Global Health microbiology drug effects Antiviral Agents Cells Medicine Infection Stomatitis Animals Virus Replication virology mortality Family Models Hepatitis C Hepatitis B |
| Language | English |
| License | Copyright © 2016, American Society for Microbiology. All Rights Reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c513t-ddbd6f16ba5c18f4a2a8ffd593e0f95bd2850b1f083f3bd31122436ec37227103 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC4810626 Citation Pécheur E-I, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ. 2016. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 90:3086–3092. doi:10.1128/JVI.02077-15. |
| ORCID | 0000-0002-2720-6661 0000-0002-8613-862X |
| OpenAccessLink | https://cir.nii.ac.jp/crid/1873961342658423936 |
| PMID | 26739045 |
| PQID | 1768558355 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4810626 hal_primary_oai_HAL_hal_01812681v1 proquest_miscellaneous_1768558355 pubmed_primary_26739045 crossref_primary_10_1128_JVI_02077_15 crossref_citationtrail_10_1128_JVI_02077_15 nii_cinii_1873961342658423936 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-03-15 |
| PublicationDateYYYYMMDD | 2016-03-15 |
| PublicationDate_xml | – month: 03 year: 2016 text: 2016-03-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Journal of Virology |
| PublicationTitleAlternate | J Virol |
| PublicationYear | 2016 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 (e_1_3_2_3_2) 1978; 56 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_50_2 Gagarinova VM (e_1_3_2_9_2) 1993; 1993 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 |
| References_xml | – ident: e_1_3_2_2_2 doi: 10.1056/NEJMc1401726 – ident: e_1_3_2_22_2 doi: 10.1371/journal.pone.0015874 – ident: e_1_3_2_47_2 doi: 10.1128/jvi.69.10.6158-6169.1995 – ident: e_1_3_2_48_2 doi: 10.1038/nm.2581 – ident: e_1_3_2_24_2 doi: 10.1126/scitranslmed.aaa5597 – ident: e_1_3_2_50_2 doi: 10.1097/00063198-200405000-00009 – ident: e_1_3_2_33_2 doi: 10.1371/journal.ppat.1001110 – ident: e_1_3_2_26_2 doi: 10.1074/jbc.M601418200 – ident: e_1_3_2_23_2 doi: 10.1016/j.tim.2015.04.006 – ident: e_1_3_2_49_2 doi: 10.1038/nm.2341 – ident: e_1_3_2_36_2 doi: 10.1128/JVI.02498-08 – ident: e_1_3_2_31_2 doi: 10.1128/JVI.00253-07 – ident: e_1_3_2_32_2 doi: 10.1016/j.virol.2007.07.014 – ident: e_1_3_2_37_2 doi: 10.1371/journal.ppat.1000512 – ident: e_1_3_2_17_2 doi: 10.1128/AAC.48.5.1766-1772.2004 – ident: e_1_3_2_46_2 doi: 10.1016/j.bmc.2005.08.041 – ident: e_1_3_2_15_2 doi: 10.1073/pnas.84.4.1005 – ident: e_1_3_2_16_2 doi: 10.1128/AAC.48.6.2199-2205.2004 – ident: e_1_3_2_43_2 doi: 10.1016/j.antiviral.2011.03.182 – ident: e_1_3_2_18_2 doi: 10.1128/AAC.00356-07 – ident: e_1_3_2_34_2 doi: 10.1371/journal.ppat.1001121 – ident: e_1_3_2_7_2 doi: 10.1093/infdis/jiu222 – ident: e_1_3_2_10_2 doi: 10.2174/092986708784049658 – ident: e_1_3_2_29_2 doi: 10.1128/JVI.77.14.7978-7990.2003 – volume: 1993 start-page: 40 year: 1993 ident: e_1_3_2_9_2 article-title: The new chemical preparation arbidol: its prophylactic efficacy during influenza epidemics publication-title: Zh Mikrobiol Epidemiol Immunobiol – ident: e_1_3_2_14_2 doi: 10.1128/AAC.00429-13 – ident: e_1_3_2_12_2 doi: 10.1016/j.bmc.2005.11.033 – ident: e_1_3_2_11_2 doi: 10.1002/jmv.22234 – ident: e_1_3_2_13_2 doi: 10.1016/j.antiviral.2014.04.006 – ident: e_1_3_2_28_2 doi: 10.1016/0042-6822(89)90286-9 – ident: e_1_3_2_39_2 doi: 10.1371/journal.ppat.1002905 – ident: e_1_3_2_19_2 doi: 10.1016/j.antiviral.2013.08.008 – ident: e_1_3_2_20_2 doi: 10.1186/1743-422X-3-56 – ident: e_1_3_2_6_2 doi: 10.1056/NEJM199505043321801 – ident: e_1_3_2_41_2 doi: 10.3390/molecules16010221 – ident: e_1_3_2_44_2 doi: 10.1038/nrmicro1645 – ident: e_1_3_2_35_2 doi: 10.1093/infdis/jir326 – ident: e_1_3_2_25_2 doi: 10.1074/jbc.M109.014647 – ident: e_1_3_2_5_2 doi: 10.1371/journal.pone.0115769 – ident: e_1_3_2_38_2 doi: 10.1111/j.1742-4658.2009.07402.x – ident: e_1_3_2_27_2 doi: 10.1007/s00018-007-7291-8 – ident: e_1_3_2_30_2 doi: 10.1016/j.cell.2005.12.038 – ident: e_1_3_2_40_2 doi: 10.1016/0042-6822(84)90102-8 – volume: 56 start-page: 247 year: 1978 ident: e_1_3_2_3_2 article-title: Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team publication-title: Bull World Health Organ – ident: e_1_3_2_4_2 doi: 10.1371/journal.pntd.0002748 – ident: e_1_3_2_8_2 doi: 10.1016/S0140-6736(12)61728-0 – ident: e_1_3_2_51_2 doi: 10.1038/nm0396-342 – ident: e_1_3_2_21_2 doi: 10.1021/bi700181j – ident: e_1_3_2_42_2 doi: 10.1016/j.antiviral.2013.08.021 – ident: e_1_3_2_45_2 doi: 10.1099/jmm.0.076612-0 |
| SSID | ssib017579904 ssib001492792 ssj0014464 ssib058493363 |
| Score | 2.5412247 |
| Snippet | Arbidol (ARB) is a synthetic antiviral originally developed to combat influenza viruses. ARB is currently used clinically in several countries but not in North... |
| SourceID | pubmedcentral hal proquest pubmed crossref nii |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3086 |
| SubjectTerms | [SDV.CAN]Life Sciences [q-bio]/Cancer Animals Antiviral Agents Antiviral Agents - pharmacology Cancer Cell Line Cells drug effects Family France Global Health Growth Hepatitis Hepatitis B Hepatitis B virus Hepatitis C Humans immunology Indoles Indoles - pharmacology Infection Laboratories Life Sciences Medicine Microbial Sensitivity Tests microbiology Models, Molecular Molecular Molecular Structure mortality Pediatrics pharmacology Stomatitis Time Vaccines and Antiviral Agents virology Virus Internalization Virus Internalization - drug effects Virus Replication Virus Replication - drug effects Viruses Viruses - drug effects |
| Title | The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses |
| URI | https://cir.nii.ac.jp/crid/1873961342658423936 https://www.ncbi.nlm.nih.gov/pubmed/26739045 https://www.proquest.com/docview/1768558355 https://hal.science/hal-01812681 https://pubmed.ncbi.nlm.nih.gov/PMC4810626 |
| Volume | 90 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb5swELbSTpP2Mu330q2TN21PERm2wZDHaN2UdOtUqW2UN4QxNGgZqZJQKfsj9jfvDgOBNpO6vaCEgA18l_Mdd_cdIe-159uRdhxr4A1Cy1G-tJSIwOcJQ1tJ6fGo6EVw8l2OLpzjqTvtdH43spbytepHv3bWlfwPqrAPcMUq2X9Ath4UdsBnwBe2gDBs74zx2SYDGw5pV4cZdoLAgvujZX7ZGy5VqhfIpDFLFYYHDL3_vCgJhKvAJIBTsP8WMDycPUmX-apMKLxtrGI1XPP9-6kJsAPiuamXuY6t8SrEKMY2TL8ABQLrrmk2NUl_IB_JJtzqvHnys2zR3MoSPsGGIZsqT7h31G--mWASU7NMbWajUgAU6tSsNUbBIn8pWmlNDWwahpaS1lSnwq54ssuvpm_ebbXPsZTheDLug_XredVVtNi1b6x6dS5i4QVxP4Czg-LsADkL7nFwOwoXffy1jkqB6-xU7PN4X1UhBfc_NudumTh7M0yw3cvSdJcPczMVt2HbnD8iD0uc6dBI2GPSibMn5L5pU7p5Ss5AzmgtZ7SWM4pyRks5o5Wc0UrOaC1ndCtntJSzZ-Tiy-fzTyOrbMZhRS4Ta0trpWXCpArdiPmJE_LQTxLtDkRsJwNXae67tmIJmPSJUFowDNkKGUfC4xzMWPGc7GeLLH5JqGZebEuVwANmjoo85fpRCCuLFjoRMEOX9KrnF0QlUz02TJkHu7Dqkg_10VeGoeUvx70DKOpDkFZ9NPwW4L6CtE767Jp1ySEgBbPilvmeGIC5C0YsmOnIFSi75G2FYQB6GINrYRYv8lXAwG93XfBnYKIXBtN6Li5hIPCdusRrod26mPYvWToruN4dn9mSy4M73uQr8mD7T3xN9tfLPD4Eq3mt3hSi_Acrhr6j |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Synthetic+Antiviral+Drug+Arbidol+Inhibits+Globally+Prevalent+Pathogenic+Viruses&rft.jtitle=Journal+of+virology&rft.au=P%C3%A9cheur%2C+Eve-Isabelle&rft.au=Borisevich%2C+Viktoriya&rft.au=Halfmann%2C+Peter&rft.au=Morrey%2C+John+D.&rft.date=2016-03-15&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=90&rft.issue=6&rft.spage=3086&rft.epage=3092&rft_id=info:doi/10.1128%2FJVI.02077-15&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_JVI_02077_15 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |